Research

Request For Proposals, August 2024

Request For Proposals relating to Single Large-Scale Mitochondrial DNA Deletion Syndromes (SLSMDS). You can also download RFP details as a PDF.

The Champ Foundation supports research toward better treatment and a cure for diseases caused by single large-scale mitochondrial DNA deletions syndromes (SLSMDS), namely Pearson Syndrome. We are releasing this RFP to find and fund the most innovative research projects aligned with this mission.

DEADLINES

RFP Release:
August 1, 2024
Submission deadline:
December 1, 2024
Awards announced and Funding Begins:
February 2025

PROPOSAL CONSIDERATIONS

  1. The probability of an advance in cure or treatment of mitochondrial DNA deletion diseases in the near term
  2. Qualifications, experiences, and abilities of the applicants
  3. The conceptual basis upon which the proposal rests
  4. The novelty of the concept and strategy
  5. Clarity and thoughtfulness of the application
  6. Adequacy of resources and environment (facilities available, access to patient samples if needed, data management, and data analysis, etc.)

PROPOSAL REQUIREMENTS

  1. Introduction letter (include scientific viability, relevance to The Champ Foundation’s mission, and likelihood of follow-up funding for the project)
  2. Project Title
  3. Project Summary
  4. Scientific Abstract
  5. Lay Abstract
  6. Detailed Budget with Amount Requested
  7. Proposal Start Date and End Date
  8. Current NIH format of biographical sketch of PI and all collaborating investigators

SUBMISSION STEPS

REVIEW DETAILS

  • Science Reviewers from the SLSMDS Family Partnership will complete a formalized review of the grants. Grant decisions are ultimately made by The Champ Foundation Board of Trustees acting on recommendations of the President and Vice President.

Funded Projects

A novel mechanism to target the mtDNA common deletion

Principal Investigators:
Brett Kaufman (University of Pittsburgh), Bruce Armitage (Carnegie Mellon) and Dr. Vincent Rotello (UMass Amherst)
Institution/Division:
University of Pittsburgh
Direct Cost Requested:
$100,000 over 1 year
Date Awarded:
July 2022
Lay Abstract:

Mitochondrial disorders can be caused by pathogenic mitochondrial DNA (mtDNA) variation (i.e., mutation), generally in a heteroplasmic state. In heteroplasmy, some mtDNA are healthy, “good,” and some are unhealthy, “bad.” A subset of sporadic mtDNA mutations lacks a substantial portion of the normal sequence, characterized as single large-scale deletions in mtDNA, which causes progressive external ophthalmoplegia (PEO), Kearns-Sayre syndrome (KSS), and Pearson syndrome (PS). There are no effective therapies or cures for patients affected by a mtDNA deletion.

The inability to remove disease-causing mtDNA sequences remains a blockade in treating mtDNA-borne disorders. Evidence suggests that eliminating bad mtDNA or adding good mtDNA can cause positive effects. While other experimental approaches are being developed, effective treatment will likely require multiple approaches. We seek to develop a specific strategy to remove bad mtDNA using molecules similar to DNA called peptide nucleic acids (PNA).

In the past, PNAs have been utilized to attempt to remove bad mtDNA; however, this approach failed because the PNAs could not reach the mtDNA. One additional issue with that approach is that PNAs have limited ability to penetrate genomic DNA. Recently, new chemistry and concepts involving gamma-substituted PNAs (γPNAs) have greatly improved this and have enabled whole animal DNA editing and somatic cell therapies, evidence of DNA penetration, and block of DNA replication. However, the current challenge is establishing efficient two-step delivery into the cell and then the mitochondria.

In this study, we will use next-generation approaches to solve the mtDNA targeting problem for a designer γPNA sequence specific to the mtDNA “common” deletion found in patients (γ-P3). Our preliminary data shows the successful adaptation of a recently described polymer strategy that yields improved delivery of γ-PNAs into the cell. Objective 1 will develop strategies to optimize polymer-mediated delivery of a fluorescent γ-P3 and establish optimal formulations for cellular delivery. Preliminary data shows no toxicity in animal models with polymer delivery. Objective 2 will synthesize and test γ-P3 with a mitochondrial import sequence on isolated mitochondria from animals and cells to establish evidence of interaction with the “bad” mtDNA. Objective 3 will determine whether the optimized delivery of γ-P3 can reduce mtDNA common deletion from a heteroplasmic cell to improve mitochondrial function. We can directly test for γ-P3 interaction with the correct template and block of replication.

Successful completion of this work will enable future in vitro studies in more relevant cell types directly applicable to patient therapy but challenging to work with for rapid γ-PNA development.

Towards eradicating mitochondrial DNA deletions via small molecule therapies.

Principal Investigators:
Ian Holt and Antonella Spinazzola
Institution/Division:
University of College London
Direct Cost Requested:
$377,955.76 over 2 years
Date Awarded:
August 2022
Lay Abstract:

Mitochondria are the parts of the cell that produce most of the energy we generate from food, and this process depends on the many small circles of DNA they contain - mitochondrial DNAs. Alterations (mutations) of mitochondrial DNA are among the most frequent causes of genetic diseases, which can manifest at any stage of life and can affect any part of the body. One type of these mutations, the single large-scale mitochondrial DNA deletions (SLSMDs), involves the loss of a large portion of the mitochondrial DNA and they can cause Pearson’s and Kearns-Sayre syndromes. Importantly, the deleted molecules coexist with normal copies, and mitochondrial malfunction and disease manifest when the damaged DNAs reach high levels. Consequently, finding a way to decrease the number of deleted mitochondrial DNAs and increase the good copies could radically improve the length and quality of life of patients with SLSMDs.

Recently, we discovered that we can cripple mitochondria that contain one type of mutant mitochondrial DNA, while permitting those with good copies of mitochondrial DNA to thrive, using compounds that change nutrient usage inside the cell. This represents an important breakthrough in mitochondrial medicine, as the compounds could benefit patients with SLSMDs.

With this project we aim to i) test the small molecules against deleted mitochondrial DNAs, in cultured cells; ii) assess the effects of one of them in a mouse that shows mitochondrial dysfunction owing to a similar kind of mutant mtDNA, and iii) discover the key changes inside the cell that select the ‘good’ mitochondrial DNAs. Achieving these goals will bring us closer to the goal of finding a cure for SLSMD Syndromes.